161 related articles for article (PubMed ID: 10588454)
1. Immunoblot analysis of natural and vaccine-induced IgG responses to rubella virus proteins expressed in insect cells.
Nedeljkovic J; Jovanovic T; Mladjenovic S; Hedman K; Peitsaro N; Oker-Blom C
J Clin Virol; 1999 Oct; 14(2):119-31. PubMed ID: 10588454
[TBL] [Abstract][Full Text] [Related]
2. Maturation of IgG avidity to individual rubella virus structural proteins.
Nedeljkovic J; Jovanovic T; Oker-Blom C
J Clin Virol; 2001 Aug; 22(1):47-54. PubMed ID: 11418352
[TBL] [Abstract][Full Text] [Related]
3. Sex differences in antibody- and cell-mediated immune response to rubella re-immunisation.
Mitchell LA
J Med Microbiol; 1999 Dec; 48(12):1075-1080. PubMed ID: 10591160
[TBL] [Abstract][Full Text] [Related]
4. The role of rubella-immunoblot and rubella-peptide-EIA for the diagnosis of the congenital rubella syndrome during the prenatal and newborn periods.
Meitsch K; Enders G; Wolinsky JS; Faber R; Pustowoit B
J Med Virol; 1997 Apr; 51(4):280-3. PubMed ID: 9093941
[TBL] [Abstract][Full Text] [Related]
5. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella.
Tischer A; Gerike E
Vaccine; 2000 Jan; 18(14):1382-92. PubMed ID: 10618536
[TBL] [Abstract][Full Text] [Related]
6. Rubella reimmunization: comparative analysis of the immunoglobulin G response to rubella virus vaccine in previously seronegative and seropositive individuals.
Mitchell LA; Ho MK; Rogers JE; Tingle AJ; Marusyk RG; Weber JM; Duclos P; Tepper ML; Lacroix M; Zrein M
J Clin Microbiol; 1996 Sep; 34(9):2210-8. PubMed ID: 8862587
[TBL] [Abstract][Full Text] [Related]
7. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection.
Cilla G; Peña B; Marimón JM; Pérez-Trallero E
Vaccine; 1996 Apr; 14(6):492-4. PubMed ID: 8782345
[TBL] [Abstract][Full Text] [Related]
8. Previous exposure to measles, mumps, and rubella--but not vaccination during adolescence--correlates to the prevalence of pancreatic and thyroid autoantibodies.
Lindberg B; Ahlfors K; Carlsson A; Ericsson UB; Landin-Olsson M; Lernmark A; Ludvigsson J; Sundkvist G; Ivarsson SA
Pediatrics; 1999 Jul; 104(1):e12. PubMed ID: 10390298
[TBL] [Abstract][Full Text] [Related]
9. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
Zäch K; Nicoara C; Germann D; Matter L
Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
[TBL] [Abstract][Full Text] [Related]
10. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
Matter L; Germann D; Bally F; Schopfer K
Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
[TBL] [Abstract][Full Text] [Related]
11. Selective tolerance to the E1 protein of rubella virus in congenital rubella syndrome.
Mauracher CA; Mitchell LA; Tingle AJ
J Immunol; 1993 Aug; 151(4):2041-9. PubMed ID: 8345195
[TBL] [Abstract][Full Text] [Related]
12. Expression of interleukin-2 receptor alpha and CD45RO antigen on T lymphocytes cultured with rubella virus antigen, compared with humoral immunity in rubella vaccinees.
Toyoda M; Ihara T; Nakano T; Ito M; Kamiya H
Vaccine; 1999 Apr; 17(15-16):2051-8. PubMed ID: 10217606
[TBL] [Abstract][Full Text] [Related]
13. Indications for measles-mumps-rubella vaccination in a child with prior thrombocytopenia purpura.
Pool V; Chen R; Rhodes P
Pediatr Infect Dis J; 1997 Apr; 16(4):423-4. PubMed ID: 9109153
[No Abstract] [Full Text] [Related]
14. Diagnostic potential of baculovirus-expressed rubella virus envelope proteins.
Seppänen H; Huhtala ML; Vaheri A; Summers MD; Oker-Blom C
J Clin Microbiol; 1991 Sep; 29(9):1877-82. PubMed ID: 1774311
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of rubella virus E2 and C proteins in protection against rubella virus in a mouse model.
Cusi MG; Valassina M; Bianchi S; Wunner W; Valensin PE
Virus Res; 1995 Aug; 37(3):199-208. PubMed ID: 8533457
[TBL] [Abstract][Full Text] [Related]
16. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
[TBL] [Abstract][Full Text] [Related]
17. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland.
Davidkin I; Peltola H; Leinikki P; Valle M
Vaccine; 2000 Jul; 18(27):3106-12. PubMed ID: 10856790
[TBL] [Abstract][Full Text] [Related]
18. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients.
King SM; Saunders EF; Petric M; Gold R
Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367
[TBL] [Abstract][Full Text] [Related]
19. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis.
Flynn JT; Frisch K; Kershaw DB; Sedman AB; Bunchman TE
Adv Perit Dial; 1999; 15():269-72. PubMed ID: 10682116
[TBL] [Abstract][Full Text] [Related]
20. Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia.
Feldman S; Andrew M; Norris M; McIntyre B; Iyer R
Clin Infect Dis; 1998 Aug; 27(2):388-90. PubMed ID: 9709893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
